<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20778" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dwarfism</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jain</surname>
            <given-names>Megha</given-names>
          </name>
          <aff>Maulana Azad Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saber</surname>
            <given-names>Ahmed Y.</given-names>
          </name>
          <aff>Calderdale and Huddersfield NHS Foundation Trust</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Megha Jain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ahmed Saber declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20778.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Dwarfism is the medical terminology for short-stature. It is defined as height-vertex below two standard deviations (-2SD) or in the third percentile for a given age and sex. The standing height is measured from ground to the vertex when the head is in the Frankfurt-horizontal plane. This activity outlines the evaluation and management of dwarfism and highlights the interprofessional team's role in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of dwarfism.</p></list-item><list-item><p>Outline the evaluation of dwarfism.</p></list-item><list-item><p>Review the management options available for dwarfism.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20778&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20778">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20778.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Dwarfism is the medical terminology for short-stature. It is defined as height-vertex below two standard deviations (-2SD) or in the third percentile for a given age and sex. The standing height is measured from ground to the vertex when the head is in the Frankfurt-horizontal plane. Most people have an aversion to the term dwarf and identify themselves as "Little people" and also have a community under the name -'Little People of America'.</p>
        <p>Dwarfism is broadly categorized into two types based on the patient's physical appearance, which are:&#x000a0;proportionate short stature (PSS) and disproportionate short stature (DSS). Proportionate short&#x000a0;stature (PSS), as the name suggests, means that the limbs and the trunk are proportionately small. Whereas, disproportionate short stature (DSS) implies that the individual has a significant difference in their sitting and standing height, and either their trunk or extremities are small. The child's assessment and evaluation aim to identify the pathological causes of short stature and intervene accordingly.</p>
      </sec>
      <sec id="article-20778.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The short stature can either be due to an underlying medical condition or a standard variant of growth. FSS, CDGP, and ISS described below can be considered as normal variants of growth, while the rest are pathological causes-</p>
        <p><bold>1. Familial Short Stature (FSS):</bold>&#x000a0;The child's genetic height potential can be measured by measuring the mid-parental height, which is a child's projected adult height based on parental height measurements. A positive family history, and the absence of underlying pathological etiologies of dwarfism, can be diagnosed as a case of familial short stature. This child has an expected growth velocity, and his bone age is consistent with the chronological age. X-Ray of the hand and wrist can establish the bone age and is a frequently used modality.</p>
        <p><bold>2. Constitutional delay of growth and puberty (CDGP):</bold>&#x000a0;The child presents with short height in childhood, but attain their target height until adulthood, also known as a 'late bloomer'. They even enter puberty at later ages. Unlike in familial cases, these children have bone age lagging behind the chronological age. Malnutrition in gestational age or childhood, even genetics, could be the plausible cause for this short stature pattern.</p>
        <p><bold>3. Idiopathic Short Stature (ISS):&#x000a0;</bold>Short stature is said to be idiopathic when no other etiology like endocrine/metabolic can be determined. With the advancements in genomic studies, it is found that many cases previously established as idiopathic can be explained by hundreds of genetic mutations with small or large effects. The role of epigenetics is also in discussion.<xref ref-type="bibr" rid="article-20778.r1">[1]</xref><xref ref-type="bibr" rid="article-20778.r2">[2]</xref></p>
        <p><bold>4. Endocrine disorders:</bold>&#x000a0;Growth hormone deficiency is a frequent cause of dwarfism. The hypothalamic-pituitary axis maintains the levels of growth hormones in the body, which then directly or indirectly, through Insulin-like growth factor-1 (IGF-1), stimulates bone elongation, and growth of soft tissue and cartilage. Lower levels of IGF-1 are linked with short stature.&#x000a0;Precocious puberty is defined as the attainment of puberty before the age of 8 years in girls and nine years in boys due to the premature release of gonadotropins centrally or peripherally. These gonadotropins lead to an initial growth spurt but also lead to the early maturation of the child's skeletal system resulting in short adult height.<xref ref-type="bibr" rid="article-20778.r3">[3]</xref></p>
        <p><bold>5. Genetic disorders</bold>: Many genetic conditions that are associated with short stature are- Down's, Turner's, Noonan's, 3-M, Prader-Willi, Russell-Silver, Aarskog, and short stature homeobox gene deficiency syndrome. Short stature is one clinical manifestation among several others.</p>
        <p><bold>6. Bone diseases:</bold>&#x000a0;The faulty formation of bone can also lead to short stature. The bone disorders linked to dwarfism are-</p>
        <p><bold>Achondroplasia:&#x000a0;</bold>It is an autosomal dominant genetic condition due to the mutation in the Fibroblast growth factor receptor-3 ( FGFR-3) gene. This gene typically limits the conversion of cartilage to bone, particularly in the long bones. In achondroplasia, this gene becomes overactive and bone formation is severely impacted in the extremities. Another cause of short-limb dwarfism is diastrophic dysplasia.<xref ref-type="bibr" rid="article-20778.r4">[4]</xref></p>
        <p><bold>Spondyloepiphyseal dysplasia:&#x000a0;</bold>It is a cause of short-trunk dwarfism with the vertebrae's primary involvement and the proximal epiphyseal centers. Type-2 collagen matrix is abnormal, but it remains unclear how this abnormality spares the distal epiphysis, given that collagen is ubiquitous.</p>
        <p><bold>7. Systemic disorders:&#x000a0;</bold>Other systemic diseases&#x000a0;which have a secondary effect on growth are undernutrition, juvenile idiopathic arthritis, inflammatory bowel disease (IBD), celiac disease, chronic kidney disease (CKD), pulmonary/cardiac/immunologic/metabolic diseases, cancers, and glucocorticoid therapy.<xref ref-type="bibr" rid="article-20778.r5">[5]</xref><xref ref-type="bibr" rid="article-20778.r6">[6]</xref><xref ref-type="bibr" rid="article-20778.r7">[7]</xref><bold>&#x000a0;</bold>Malnutrition can dampen the growth velocity and&#x000a0;cause short stature. It can affect the baby in the gestational period, leading to underweight or small for gestational age (SGA) baby, or in childhood leading to stunted growth.<xref ref-type="bibr" rid="article-20778.r8">[8]</xref></p>
      </sec>
      <sec id="article-20778.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>In the United States, 2.5 percent of the population is short. The Utah Study, a population-based survey of growth in children, concluded that endocrine disorders constitute only a small number of cases with short stature. People of both sexes are affected, but males are more likely to be brought to medical attention because of the prevalence of social expectations.<xref ref-type="bibr" rid="article-20778.r9">[9]</xref></p>
        <p>Different ethnic groups have different average statures, which are essential to take into consideration while comparing mean parameters. Because these variations exist, it is recommended to compare the height of an individual with people from the same population only, if specific growth charts are available&#x000a0;. Malnutrition is a notable etiology of retarded growth in kids, especially in developing countries. Many efforts have been in process by the government and non-profit organizations to curb this.<xref ref-type="bibr" rid="article-20778.r10">[10]</xref></p>
      </sec>
      <sec id="article-20778.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The linear growth of an individual depends on the equilibrium between proliferation and senescence of cartilage cells at the growth plate. Multiple mechanisms regulate this process-</p>
        <list list-type="bullet">
          <list-item>
            <p>Endocrine pathways &#x02013; The hormones which promote chondrogenesis are GH, IGF-1, androgens, T3/T4 (thyroid hormones), while glucocorticoids inhibit chondrogenesis. Estrogen stimulates the release of GH and IGF-1 but also promotes chondrocyte senescence and epiphyseal fusion, and suspension of linear growth. Therefore, precocious puberty is associated with an initial growth spurt but an ultimate short adult height.<xref ref-type="bibr" rid="article-20778.r11">[11]</xref><xref ref-type="bibr" rid="article-20778.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Proinflammatory cytokines &#x02013; The chronic inflammatory conditions have elevated proinflammatory cytokines, which negatively impact the linear growth. As inflammation ceases, the cytokine levels drop, and the patient can catch up on growth.<xref ref-type="bibr" rid="article-20778.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Paracrine mechanisms &#x02013; GH-IGF-1 axis is only one of the many regulatory pathways of height gain. Many autocrine and paracrine pathways are under research; mutation of these can lead to short stature or tall stature. These include many intracellular and extracellular matrix proteins like fibroblast growth factors (FGF), bone morphogenetic proteins (BMP), parathyroid hormone-related protein (PTH-RP), collagens, and proteoglycans in the cartilage extracellular matrix.</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Intracellular pathways &#x02013; SHOX gene codes for transcription factors that regulate the activity of other genes and its mutation is associated with a spectrum of clinical manifestations with Leri-Weill dyschondrosteosis (LWD) on the critical end, and nonspecific short stature on the other. LWD is a classical triad of short stature, mesomelia, and Madelung deformity.<xref ref-type="bibr" rid="article-20778.r14">[14]</xref> Different signaling pathways that can be affected are SOX genes, MAPK pathways.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20778.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A thorough clinical history is vital in establishing the cause of dwarfism. The child's clinical record should include relevant data from gestation to birth, developmental milestones, and puberty emergence. A pedigree chart can be formulated to mention the family history of short stature. A psychological assessment of the patient is crucial as this disorder is associated with social stigmatization and extensive mental pressure. Anthropometric measurements are a part of regular child visits. These measurements include body weight, height vertex, truncal height, and limb length, plotted on a growth chart to compare with the mean parameters for that age, sex, and population.</p>
      </sec>
      <sec id="article-20778.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>T</bold>
<bold>he child under evaluation undergoes a series of biochemical and radiological tests:</bold>
</p>
        <p>
<bold>Biochemical Tests</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete blood count for hematological diseases like anemia.</p>
          </list-item>
          <list-item>
            <p>Sweat chloride test for cystic fibrosis. Patients usually have a history of meconium ileus and pulmonary symptoms.</p>
          </list-item>
          <list-item>
            <p>Serum thyrotropin (TSH) levels and free thyroxine levels (T4) to test for hypothyroidism.</p>
          </list-item>
          <list-item>
            <p>Wintrobe sedimentation rate for inflammatory bowel disease (IBD)</p>
          </list-item>
          <list-item>
            <p>Antibody testing for celiac sprue includes anti-endomysial immunoglobulin A (IgA), immunoglobulin G (IgG), and anti-gliadin IgG titers. Antiendomysial IgA titers are more sensitive, and IgG titers are more specific.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Serum pre-albumin and transferrin- These values are low in undernutrition.&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Imaging</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Anteroposterior X-ray of the left hand and wrist</bold>: It is used to predict the bone age. The radiologist uses the Greulich and Pyle or Tanner-Goldstein-Whitehouse method to calculate the bone age and forecast adult height. While the prior is a more straightforward method, the latter is more reliable.<xref ref-type="bibr" rid="article-20778.r15">[15]</xref><xref ref-type="bibr" rid="article-20778.r16">[16]</xref><xref ref-type="bibr" rid="article-20778.r17">[17]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>MRI</bold>&#x000a0;can provide evidence of any intracranial masses (craniopharyngiomas)or developmental anomalies of the pituitary. Before the GH therapy is initiated, an MRI scan should be ordered to rule out any organic lesions.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Karyotyping:&#x000a0;</bold>It can detect genetic disorders like Down syndrome, Turner syndrome, and others.&#x000a0;</p>
            <p><bold>Provocative tests:&#x000a0;</bold>&#x000a0;These tests are used to measure the GH reserve, but their utility is limited. They are not reproducible and do not determine the physiological secretory pattern of GH. These include- insulin tolerance test, Levodopa-propanol HCL test, Arginine HCL test, Glucagon test. Other physiological stimuli that can be used are strenuous exercise, deep sleep, and fasting. The levels of growth hormone fluctuate throughout the day, and peaks after meals, after strenuous exercise, and in a deep sleep. This property makes it an unreliable biomarker for detecting growth hormone deficiency (GHD); however, stimulated GH values of more than 10mg/dl can essentially rule out the deficit. Therefore, more predictive markers are serum IGF-1 levels (somatomedin C) and insulin-like growth factor binding protein-3 (IGFBP-3) levels. IGFBP-3 has more specificity than IGF-1. In patients in the pubertal phase, with CNS neoplasms, and poor nutrition, these markers can be abnormally high even in the presence of GHD and are unreliable.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20778.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There are various treatment options available to these kids to achieve the best possible outcomes for them. These includes:</p>
        <p>
<bold>Hormonal Therapy</bold>
</p>
        <p>Recombinant human growth hormone therapy (rhGH) is an effective treatment for patients suffering from growth hormone deficiency. Early intervention can prevent short stature and the psychosocial stress associated with it. The clinical benefits of rhGH are controversial, so its fixed dosing is based on its weight. Newer reports propose that rhGH dosing based on the children's IGF levels may be safe and provide superior outcomes. For patients with idiopathic short stature (ISS), commencing GH therapy can enhance the growth velocity and mean adult height. Hence, it might be suitable to say that the decision to give rhGH does not only depend on the etiology of short stature, i.e., whether it is due to ISS or GHD but also on the status of the epiphyseal maturation, mid-parental height, etc.these markers can be abnormally high even in the presence of GHD and are unreliable.<xref ref-type="bibr" rid="article-20778.r18">[18]</xref><xref ref-type="bibr" rid="article-20778.r19">[19]</xref></p>
        <p>Gonadotropin-releasing hormone (GnRH) analogs are used to halt the progression of precocious puberty. When administered, these analogs continuously suppress the release of gonadotropins from the pituitary and further down the gonadal steroids, which were responsible for premature bone maturation.</p>
        <p>
<bold>Surgical Treatment</bold>
</p>
        <p>Brain tumors need neurosurgery intervention. The limb-lengthening procedures are not recommended as they have high morbidity and mortality.</p>
      </sec>
      <sec id="article-20778.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses for dwarfism include the following:</p>
        <list list-type="order">
          <list-item>
            <p><bold>Endocrine disorders</bold>: Growth hormone deficiency, congenital hypothyroidism, Cushing syndrome, hypogonadism.</p>
          </list-item>
          <list-item>
            <p><bold>Genetic disorders</bold>: Down's, Turner's, Noonan's, 3-M, Prader-Willi, Russell-Silver, Aarskog, and short stature homeobox gene deficiency syndrome.</p>
          </list-item>
          <list-item>
            <p><bold>Bone disorders</bold>: Achondroplasia, Diastrophic dysplasia, Spndyloepiphyseal dysplasia.</p>
          </list-item>
          <list-item>
            <p><bold>Chronic conditions</bold>: Chronic renal insufficiency, chronic malnutrition, cystic fibrosis, juvenile idiopathic arthritis, inflammatory bowel disease, celiac disease, pulmonary/cardiac/immunologic/metabolic diseases, cancers, and glucocorticoid therapy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20778.s10" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>The child receives daily subcutaneous growth hormone (GH) injections, and are advised to take GH injections regularly, preferably within 1 hour of sleep every night, at a specific time, and not to miss more than one dose a month. The patient usually follows-up 2&#x000a0;to 4 times a year. The growth rate is maximum in the first year of treatment, ranging from 8-10cm/year; this is called 'catch-up growth.' The growth rate slows in the next several years, called the 'waning effect.' If the growth rate is slower than expected, it warrants further investigation to rule out other medical conditions like Hypothyroidism or IBD. The treatment continues until the patient reaches her full adult height or reaches full bone maturity or has grown less than 2 cm in the last year.</p>
      </sec>
      <sec id="article-20778.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The normal variants of short stature can expect to lead healthy lives. The patients suffering from GHD can benefit from recombinant human growth hormone therapy and generally attain heights similar to their parents, given that the treatment is commenced before puberty. The short stature secondary to genetic and skeletal disorders cannot be reversed and remains a life long issue.</p>
      </sec>
      <sec id="article-20778.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Short stature may be an indicator of chronic occult disease and need a thorough workup. These children have a lower bone density than the taller population, but its association with osteoporosis is unclear. Other common complications associated with disproportionate dwarfism are bowed legs, arthritis, kyphosis, spinal stenosis, syringomyelia, sleep apnea, hydrocephalus, weight gain.</p>
        <p>The complications which are associated with GH therapy are- possible predisposition to type-2 diabetes, benign intracranial hypertension, edema/carpal tunnel syndrome, slipped capital femoral epiphysis (SCFE), scoliosis, prepubertal gynecomastia. Management of these complications can be done by temporary therapy termination until resolving symptoms and restarting later at lower doses.</p>
      </sec>
      <sec id="article-20778.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>The following consultations are required:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric cardiologist, radiologist, and audiologist for patients with Turner syndrome.</p>
          </list-item>
          <list-item>
            <p>Consult a psychologist for patients with mental&#x000a0;illnesses and those facing psychosocial stressors.<xref ref-type="bibr" rid="article-20778.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Pediatric endocrinologist for GHD workup and provocative testing.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20778.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The patients and family members should be educated about the clinical basis, aetiologies, and treatment options for short stature. For patients who are planned for growth hormone therapy should be informed about the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>The GH used in treatment is similar to GH released from the pituitary gland and is safe and effective.</p>
          </list-item>
          <list-item>
            <p>The patient can experience foot growth within 6-8 weeks of treatment, increase appetite, increase lean body mass, and decrease fat.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Routine consults with the pediatric endocrinologist, blood test, and X-ray to monitor the child's progress.</p>
          </list-item>
          <list-item>
            <p>Long term commitment to the treatment.</p>
          </list-item>
          <list-item>
            <p>Importance of compliance for best outcomes.</p>
          </list-item>
          <list-item>
            <p>The patient needs to be informed about the administration technique, injection sites, timings, and the drug's refrigerating requirements for optimum efficacy.</p>
          </list-item>
          <list-item>
            <p>The possible side effects-&#x000a0;</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Allergic reaction, rash, or swelling at the injection site.</p>
              </list-item>
              <list-item>
                <p>Hip, knee, or other joint pain indicative of slipped capital femoral epiphysis.</p>
              </list-item>
              <list-item>
                <p>Headache may be indicative of benign intracranial hypertension.</p>
              </list-item>
              <list-item>
                <p>Progression of scoliosis.</p>
              </list-item>
              <list-item>
                <p>Temporary increase in blood sugar levels. Management of these complications can be done by temporary therapy termination until resolving symptoms and restarting later at lower doses.</p>
              </list-item>
            </list>
          </list-item>
        </list>
      </sec>
      <sec id="article-20778.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The physicians working&#x000a0;in&#x000a0;children's healthcare need alertness to detect errant growth rates and provide patient-centered interventions. These kids require long term monitoring, documentation in the growth charts, and physicians' judgment of employing growth hormone therapy. Regular counseling sessions help to educate the patient and family members and improve the outcomes. The psychologist and psychiatrist may need to intervene in children facing psychosocial stressors, eating disorders, and other mental illnesses.<xref ref-type="bibr" rid="article-20778.r20">[20]</xref></p>
      </sec>
      <sec id="article-20778.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20778&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20778">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/dwarfism/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20778">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20778/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20778">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20778.s17">
        <title>References</title>
        <ref id="article-20778.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wit</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Clayton</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Rogol</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Saenger</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic short stature: definition, epidemiology, and diagnostic evaluation.</article-title>
            <source>Growth Horm IGF Res</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-110</page-range>
            <pub-id pub-id-type="pmid">18182313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hwang</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Amano</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Shim</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Nam</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Rhie</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Role of NPR2 mutation in idiopathic short stature: Identification of two novel mutations.</article-title>
            <source>Mol Genet Genomic Med</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>e1146</fpage>
            <pub-id pub-id-type="pmid">31960617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Grumbach</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Clinical review 14: Pathophysiology and treatment of sexual precocity.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1990</year>
            <month>Oct</month>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>785</fpage>
            <page-range>785-9</page-range>
            <pub-id pub-id-type="pmid">2205623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ornitz</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Legeai-Mallet</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Achondroplasia: Development, pathogenesis, and therapy.</article-title>
            <source>Dev Dyn</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>246</volume>
            <issue>4</issue>
            <fpage>291</fpage>
            <page-range>291-309</page-range>
            <pub-id pub-id-type="pmid">27987249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bechtold</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Natural history of growth and body composition in juvenile idiopathic arthritis.</article-title>
            <source>Horm Res</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>72 Suppl 1</volume>
            <fpage>13</fpage>
            <page-range>13-9</page-range>
            <pub-id pub-id-type="pmid">19940490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vasseur</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gower-Rousseau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vernier-Massouille</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dupas</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Merle</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Merlin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lerebours</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Savoye</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salomez</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cortot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colombel</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Turck</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Nutritional status and growth in pediatric Crohn's disease: a population-based study.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>105</volume>
            <issue>8</issue>
            <fpage>1893</fpage>
            <page-range>1893-900</page-range>
            <pub-id pub-id-type="pmid">20145606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Growth suppression by glucocorticoid therapy.</article-title>
            <source>Endocrinol Metab Clin North Am</source>
            <year>1996</year>
            <month>Sep</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>699</fpage>
            <page-range>699-717</page-range>
            <pub-id pub-id-type="pmid">8879994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x0015e;&#x00131;klar</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Berbero&#x0011f;lu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Syndromic disorders with short stature.</article-title>
            <source>J Clin Res Pediatr Endocrinol</source>
            <year>2014</year>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">24637303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grimberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feemster</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Pati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grundmeier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cucchiara</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Stallings</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>Medically underserved girls receive less evaluation for short stature.</article-title>
            <source>Pediatrics</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>127</volume>
            <issue>4</issue>
            <fpage>696</fpage>
            <page-range>696-702</page-range>
            <pub-id pub-id-type="pmid">21422085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000e9;rez-R&#x000ed;os</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Santiago-P&#x000e9;rez</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Malvar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hervada</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>[Prevalence of malnutrition in Spanish schoolchildren].</article-title>
            <source>An Pediatr (Engl Ed)</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>90</volume>
            <issue>4</issue>
            <fpage>259</fpage>
            <page-range>259-260</page-range>
            <pub-id pub-id-type="pmid">30503667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerrigan</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Rogol</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>The impact of gonadal steroid hormone action on growth hormone secretion during childhood and adolescence.</article-title>
            <source>Endocr Rev</source>
            <year>1992</year>
            <month>May</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>281</fpage>
            <page-range>281-98</page-range>
            <pub-id pub-id-type="pmid">1618164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nilsson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Weise</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Landman</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Evidence that estrogen hastens epiphyseal fusion and cessation of longitudinal bone growth by irreversibly depleting the number of resting zone progenitor cells in female rabbits.</article-title>
            <source>Endocrinology</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>155</volume>
            <issue>8</issue>
            <fpage>2892</fpage>
            <page-range>2892-9</page-range>
            <pub-id pub-id-type="pmid">24708243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sederquist</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fernandez-Vojvodich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zaman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>S&#x000e4;vendahl</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Recent research on the growth plate: Impact of inflammatory cytokines on longitudinal bone growth.</article-title>
            <source>J Mol Endocrinol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>T35</fpage>
            <page-range>T35-44</page-range>
            <pub-id pub-id-type="pmid">24711646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munns</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Glass</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Flanagan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vickers</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>O'Rourke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rappold</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Hyland</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Batch</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Familial growth and skeletal features associated with SHOX haploinsufficiency.</article-title>
            <source>J Pediatr Endocrinol Metab</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>987</fpage>
            <page-range>987-96</page-range>
            <pub-id pub-id-type="pmid">14513875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinchi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>De Luca</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ricciardi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Focardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piredda</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mazzeo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Norelli</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Skeletal age estimation for forensic purposes: A comparison of GP, TW2 and TW3 methods on an Italian sample.</article-title>
            <source>Forensic Sci Int</source>
            <year>2014</year>
            <month>May</month>
            <volume>238</volume>
            <fpage>83</fpage>
            <page-range>83-90</page-range>
            <pub-id pub-id-type="pmid">24681971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>BAYLEY</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>PINNEAU</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards.</article-title>
            <source>J Pediatr</source>
            <year>1952</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>423</fpage>
            <page-range>423-41</page-range>
            <pub-id pub-id-type="pmid">14918032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dahlberg</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Mosd&#x000f8;l</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Bleka</surname>
                <given-names>&#x000d8;</given-names>
              </name>
              <name>
                <surname>Rolseth</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Straumann</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Skjerven&#x02010;Martinsen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Delaveris</surname>
                <given-names>GJM</given-names>
              </name>
              <name>
                <surname>Vist</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <source>Agreement Between Chronological Age and Bone Age Based on the Greulich and Pyle Atlas for Age Estimation: A Systematic Review [Internet]</source>
            <publisher-name>Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH)</publisher-name>
            <publisher-loc>Oslo, Norway</publisher-loc>
            <year>2017</year>
            <month>03</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">29553681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rogol</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Deal</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Saenger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reiter</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chernausek</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Wit</surname>
                <given-names>JM</given-names>
              </name>
              <collab>2007 ISS Consensus Workshop participants</collab>
            </person-group>
            <article-title>Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>93</volume>
            <issue>11</issue>
            <fpage>4210</fpage>
            <page-range>4210-7</page-range>
            <pub-id pub-id-type="pmid">18782877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toumba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Albanese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Azcona</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stanhope</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effect of long-term growth hormone treatment on final height of children with Russell-Silver syndrome.</article-title>
            <source>Horm Res Paediatr</source>
            <year>2010</year>
            <volume>74</volume>
            <issue>3</issue>
            <fpage>212</fpage>
            <page-range>212-7</page-range>
            <pub-id pub-id-type="pmid">20424422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20778.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quitmann</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Bullinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sommer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rohenkohl</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Bernardino Da Silva</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Associations between Psychological Problems and Quality of Life in Pediatric Short Stature from Patients' and Parents' Perspectives.</article-title>
            <source>PLoS One</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>e0153953</fpage>
            <pub-id pub-id-type="pmid">27097033</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
